公开(公告)号：US20210069180A1

公开(公告)日：2021-03-11

申请号：US16992005

申请日：2020-08-12

Applicant: GRIFFITH UNIVERSITY

Inventor： Sonya M. Marshall-Gradisnik ,  Donald R. Staines ,  Peter Kenneth Smith ,  Helene Marie Cabanas

IPC: A61K31/485

Abstract: In one aspect the invention relates to a method of treatment selected from the group consisting of: (a) treating a symptom such as pain in a subject identified or diagnosed as having Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS); (b) treating a symptom such as pain in a subject having dysfunctional TRPM3 ion channel activity; (c) restoring NK cell function in a subject having dysfunctional TRPM3 ion channel activity; and (d) restoring calcium homeostasis in a subject having dysfunctional TRPM3 ion channel activity. The method comprises the step of administering to the subject a therapeutically effective amount of at least one therapeutic compound selected from the group consisting of: (i) an opioid receptor antagonist; (ii) an opioid antagonist; and (iii) a therapeutic compound that restores TRPM3 ion channel activity. In some embodiments the therapeutic compound is naltrexone hydrochloride.